B/F/TAF for HIV (BEST-HBV Trial)

"According to the information posted on clinicaltrials.gov, this medical study has concluded its patient recruitment as it was last updated on July 13th 2022. Nevertheless, there are still 491 other active trials in need of participants at present time."

"B/F/TAF is an anti-retroviral medication prescribed for a range of illnesses, including HIV 1 and those lacking resistance to darunavir. This drug can also be used as a first line treatment option in many cases."

"There is existing evidence demonstrating the safety of B/F/TAF, thus it has been assigned a rating of 3. This Phase 4 trial implies that this treatment has already achieved regulatory approval."

"This study has already ceased to search for participants, with the initial post date being April 30th 2019 and final update occurring on July 13th 2022. For those interested in other clinical trials, 393 studies are actively searching for patients affected by hepatitis b while 98 researches seek volunteers infected with B/F/TAF."

"Initially studied at University of Zurich in 2002, B/F/TAF has since been researched extensively with 358 studies being concluded and 98 more currently underway. Philadelphia, Pennsylvania is a major hub for these live clinical trials."

"This trial's main evaluation point is the participants' HIV-1 RNA levels taken 24 weeks into the study. Secondary assessments include a comparison of ALT normalization at Week 24, HBeAg loss by Week 48, and again measuring for ALT regularity after 48 weeks."